Introduction Preclinical studies have suggested that the oral antifungal agent itraconazole
specifically inhibits proliferation, migration, and tube formation of endothelial cells …

The antiangiogenic agent bevacizumab has been approved for the treatment of non–small
cell lung cancer (NSCLC), although the survival benefit associated with this agent is …

Purpose: To determine efficacy and toxicity of two pemetrexed-based regimens in
chemonaive patients with locally advanced or metastatic non–small cell lung cancer …

Background Pemetrexed plus cisplatin was approved for first-line treatment of non–small-
cell lung cancer (NSCLC) in patients with nonsquamous histology after initiation of this …

Background To evaluate the efficacy and safety of pemetrexed therapy for chemotherapy-
naïve patients with surgically incurable non-small-cell lung cancer (NSCLC). Patients and …

Introduction: This randomized open-label phase II study evaluated the efficacy, safety, and
tolerability of pazopanib in combination with pemetrexed compared with the standard …

Importance of the field: Current therapeutic options for advanced non-small-cell lung cancer
(NSCLC) yield relatively modest improvements in survival leading to an ongoing search for …

Objective Pemetrexed has been approved for second-line treatment in non-small cell lung
cancer (NSCLC). However, the role of third-line pemetrexed therapy in NSCLC has not yet …

Purpose: Platinum-based regimens represent the standard first-line treatment for non-small-
cell lung cancer (SNCLC). However, newer data have established a role for pemetrexed in …

Abstract On September 26, 2008, the US Food and Drug Administration approved
pemetrexed injection (Alimta® Injection; Eli Lilly and Company, Indianapolis, IN) for use in …